Pentabind

PentaBind is a London-based company that designs aptamers — short laboratory-engineered DNA strands that bind specific target molecules — using a combination of generative AI models and in-house wet-lab validation. Its commercial offering, marketed as the SenseReady portfolio, consists of aptamer 'assets' licensed to companies building continuous molecular sensing and diagnostic products. The company distinguishes these assets from research-grade 'in-buffer binders', stating that each licensed asset is engineered to meet defined performance characteristics and is delivered with a technical datasheet covering affinity, specificity, limit of detection, selectivity against interferents, and validated performance in the biological matrix relevant to the customer's device (for example interstitial fluid, sweat or blood, at body temperature).

The published SenseReady portfolio covers four analyte families with stated clinical ranges: estradiol (0.01–0.6 ng/mL), progesterone (0.1–25 ng/mL), lactate (0.05–1.8 mg/mL) and creatinine (5–100 µg/mL). The estradiol, progesterone and lactate families are described as available for licensing, while the creatinine family is described as exclusively licensed. Named use cases are metabolic health (continuous biomarker sensing for precision dosing), hormonal health, and therapeutic drug monitoring and dose adjustment.

In parallel with the sensing business, PentaBind has been described as a TechBio drug development company applying generative AI to design aptamer-based therapeutics, including against protein targets considered undruggable by conventional modalities, with potential oncology applications in which aptamers would target cancer cells selectively.